Trial Profile
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Zanolimumab (Primary) ; Aldesleukin
- Indications Malignant melanoma; Renal cell carcinoma
- Focus Therapeutic Use
- 14 Mar 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 14 Mar 2012 Additional lead trial investigator (Schrump DS) identified as reported by ClinicalTrials.gov.
- 05 Jan 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.